Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Daiichi Sankyo
Dow
Medtronic
US Army
Johnson and Johnson
US Department of Justice
Argus Health

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,129,362

« Back to Dashboard

Which drugs does patent 8,129,362 protect, and when does it expire?

Patent 8,129,362 protects EPIDUO and is included in one NDA.

This patent has twenty-two patent family members in eighteen countries.
Summary for Patent: 8,129,362
Title:Combination/association of adapalene and benzoyl peroxide for treating acne lesions
Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).
Inventor(s): Chacra Vernet; Marie-Line Abou (Nice, FR), Gross; Denis (Callian, FR), Loesche; Christian (Valbonne, FR), Poncet; Michel (Mougins, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:11/826,364
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,129,362
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 8,129,362

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp EPIDUO adapalene; benzoyl peroxide GEL;TOPICAL 022320-001 Dec 8, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ACNE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,129,362

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France06 52968Jul 13, 2006

Non-Orange Book US Patents Family Members for Patent 8,129,362

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,445,543 Combinations of adapalene and benzoyl peroxide for treating acne lesions ➤ Sign Up
8,071,644 Combinations of adapalene and benzoyl peroxide for treating acne lesions ➤ Sign Up
8,785,420 Combination/association of adapalene and benzoyl peroxide for treating acne lesions ➤ Sign Up
8,080,537 Combinations of adapalene and benzoyl peroxide for treating acne lesions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,129,362

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2046318 ➤ Sign Up
Russian Federation 2012144414 ➤ Sign Up
Russian Federation 2012136952 ➤ Sign Up
Russian Federation 2009104949 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKinsey
Cantor Fitzgerald
Cerilliant
QuintilesIMS
Julphar
Baxter
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.